A Phase 2 interventional study of Duvelisib, Chidamide in Newly Diagnosed Peripheral T-cell Lymphoma, sponsored by Liling Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Liling Zhang · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral — 17 open to participants now, 18 under way, 2 of them phase 3. tucidinostat · Lymphoma, T-Cell, Peripheral.
Among the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, this one is the 18th largest by planned enrollment, is one of 5 that started in 2023, is one of 16 in phase 2, reaches primary completion later than 6 of the 17 other live ones, and was the 20th registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →17 of the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Chipscreen Biosciences, Ltd. · Sites in China
Ages 18–80
Great Novel Therapeutics Biotech & Medicals Corporation · Sites in Taiwan
Ages 20–75
Yanyan Liu · Sites in China
Ages 18–80
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 22 · Phase 3 3
First in 2015; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 44 across the 29 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 29 have an industry lead sponsor. The 10 most frequent:
Liling Zhang is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Liling Zhang has 1 study filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
5 of the studies testing tucidinostat in Lymphoma, T-Cell, Peripheral that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05958719Institute of Hematology & Blood Diseases Hospital, ChinaChidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma | 2026-12-30 |
| NCT06421948Yanyan LiuLinperlisib Combined With Chidamide in Patients With PTCL | 2027-05-31 |
| NCT05833724Great Novel Therapeutics Biotech & Medicals CorporationChidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) | 2027-06 |
| NCT07093710Sun Yat-sen UniversityGolidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | 2027-08-01 |
| NCT07139353Sun Yat-sen UniversityLinperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 29 studies testing tucidinostat in Lymphoma, T-Cell, Peripheral, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.
This is a prospective, single arm, single center study, including two phases. It plans to recruit36 patients with clinically diagnosed primary PTCL who will be treated with Duvelisib and Chidamide. In the first phase Duvelisib is Oral administration at a dose of 25mg twice a day, and every 4 weeks (28 days) was a cycle. Next administration will be depend on whether the efficacy reaches CR in the second phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
1.Age: 18-70 Years (Contains boundary values 18 and 70);
2.The newly diagnosed PTCL confirmed by histopathology is one of the following subtypes;
a) Angioimmunoblastic T-cell lymphoma (AITL); b) Follicular T helper cell lymphoma (T-FHCL); Including but not limited to the above two subtypes;
Exclusion Criteria:
-
1.Subjects who have previously received systemic treatment for lymphoma or currently undergoing anticancer treatment;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with newly diagnosed PTCL were treated with a combination of Duvelisib and Chidamide. The dose of Duvelisib was 25mg twice a day. Every 4 weeks (28 days) is a cycle with a total of 2 cycles.
Drug: Duvelisib, Chidamide
Drug pages: DuvelisibStudies of DuvelisibDuvelisib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TucidinostatStudies of TucidinostatTucidinostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Duvelisib, 25mg, BID, PO; Chidamide, 20mg, BIW, PO;
Safety: Hematologic and non-hematologic toxicities (NCI CTCAE v5.0)
To identify the incidence of AE and SAE in clinical trial
Time frame: from the initiation of the first dose to 28 days after the last dose
Objective response rate (ORR)
To evaluate the efficacy of anti-lymphoma
Time frame: up to 26 weeks
Complete remission rate (CR)
To evaluate the efficacy of anti-lymphoma
Time frame: up to 26 weeks
Duration of Response(DOR)
To evaluate the efficacy of anti-lymphoma
Time frame: The time from the first assessment as CR or PR to the first assessment as PD or death (due to any cause),assessed up to 12 months
Progression free survival (PFS)
To evaluate the efficacy of anti-lymphoma
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
Overall survival (OS)
To evaluate the efficacy of anti-lymphoma
Time frame: From date of randomization until the date of death from any cause, assessed up to 20 months
Started May 2023 (actual). Primary completion is estimated for Oct 2026, 41 months after the start.
Of 44 non-industry phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 110. This study's planned 41 months is below that.
Counting every sponsor, half of 64 studies reached it within 61 months; a quarter within 38 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Duvelisib · Tucidinostat
Lymphoma, T-Cell, Peripheral →
Liling Zhang